Compare Gilead Sciences, Inc. (GILD) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Remitly Global Inc — how do they compare? Gilead Sciences, Inc. trades at $135.47 (market cap $163.51B), while Remitly Global Inc trades at $25.68 (market cap $5.26B). The key difference: Gilead Sciences, Inc. is far larger — about 31.1× Remitly Global Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| GILD | RELY | |
|---|---|---|
Market Cap | $163.51B | $5.26B |
Sector | Health | Technology |
52-Week High | $155.80 | $24.96 |
52-Week Low | $108.22 | $12.20 |
Enterprise Value | $178.05B | $4.65B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
RELY stock trades at $25.57, up 8.72% in the last 24 hours, showing strong momentum. The company demonstrates accelerating revenue growth from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Technical indicators show bullish momentum with the current price near resistance at $26. Recent expansion into UAE and Canadian markets positions the company for continued international growth.
RELY presents a compelling growth story with improving profitability and strong analyst support (92% buy ratings). However, elevated valuation multiples (P/E 52) and competitive pressures in the remittance space warrant caution. The stock's upside potential to the $27.40 consensus target appears reasonable given accelerating revenue and expanding margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
